Response to therapy in demyelinating motor neuropathy

Authors

  • Lisa Markson MD, FRCP(C),

    1. The Toronto Hospital, General Division, EN11-209, 200 Elizabeth Street, Toronto, Ontario M5G 2C4 Canada
    Search for more papers by this author
  • Donna Janzen BSc, RT(EMG),

    1. The Toronto Hospital, General Division, EN11-209, 200 Elizabeth Street, Toronto, Ontario M5G 2C4 Canada
    Search for more papers by this author
  • Vera Bril MD, FRCP(C)

    Corresponding author
    1. The Toronto Hospital, General Division, EN11-209, 200 Elizabeth Street, Toronto, Ontario M5G 2C4 Canada
    • The Toronto Hospital, General Division, EN11-209, 200 Elizabeth Street, Toronto, Ontario M5G 2C4 Canada
    Search for more papers by this author

Abstract

We reviewed results of immunotherapy in patients with demyelinating motor neuropathy (DMN), and found that patients over 50 years of age at onset responded poorly, and younger patients responded variably to intervention. We suggest that patients with DMN be given a guarded prognosis, particularly if >50 years of age at onset. © 1998 John Wiley & Sons, Inc. Muscle Nerve 21: 1769–1771, 1998

Ancillary